Metabolic buffering suppresses phenotype switching in cancer
Authors:
- Ana Ramírez-SánchezARAna Ramírez-Sánchez
- Miguel Jociles-OrtegaMJMiguel Jociles-Ortega
- José Manuel García-MartinezJGJosé Manuel García-Martinez
- Irene Torrens-MartínezITIrene Torrens-Martínez
- Javier Martínez-UserosJavier Martínez-Useros
- María Jesús Fernández-AceñeroMFMaría Jesús Fernández-Aceñero
- Pakavarin LouphrasitthipholPLPakavarin Louphrasitthiphol
- Colin R. GodingCGColin R. Goding
- Custodia García-JiménezCGCustodia García-Jiménez
- Ana Chocarro-CalvoACAna Chocarro-Calvo
Preprint
Abstract
The impact of the microenvironment on epigenetically plastic cancer cells underpins phenotypic heterogeneity, a major cause of metastatic dissemination and therapy resistance that together represent the primary cause of cancer-related death. Nutrient limitation is a key microenvironmental stress that can cause a phenotypic transition from proliferation to invasion via activation of the integrated stress response. However, whether and how the capacity to store and mobilize nutrients impacts phenotype-switching through metabolic buffering remains unknown. Here, using melanoma as a model, we reveal that the ability to accumulate and mobilize glycogen, that buffers glucose availability, plays a key role in phenotypic transitions in melanoma. While proliferative phenotype cells exhibit high levels of glycogen, invasion is marked by low glycogen levels. Significantly, an inability to store and metabolize glycogen leads to phenotype instability and a switch to invasion. Accordingly, glycogen levels inversely correlate with Clark levels in primary melanomas, with low expression of the glycogen phosphorylases PYGB/L and phosphoglucomutase 1 (PGM1) being associated with worse overall survival. The importance of metabolic buffering in suppressing phenotypic transitions likely extrapolates to other cancer types. Highlights: Melanoma phenotypes are distinguished by their ability to store and mobilize glycogen. Proliferative MITF High melanoma cells store glycogen to improve survival under stressful conditions. Inhibition of glycogen degradation impairs proliferation in MITF High melanoma cells. Lack of PGM1 drives invasion and metastatic dissemination.Keywords
This publication has 47 references indexed in Scilit:
- The role of tumor-associated macrophages in tumor immune evasionJournal of Cancer Research and Clinical Oncology, 2024
- Glycogen accumulation and phase separation drives liver tumor initiationCell, 2021
- AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvationCancer Letters, 2020
- Glycogen phosphorylase B promotes ovarian cancer progression via Wnt/β-catenin signaling and is regulated by miR-133a-3pBiomedicine & Pharmacotherapy, 2019
- Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative StressCancer Cell, 2018
- Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapyJournal of Molecular Medicine, 2016
- Glycogen metabolism in cancerBiochemical Pharmacology, 2014
- Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma?Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2011
- A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridolCancer Chemotherapy and Pharmacology, 2010
- A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109Cancer Chemotherapy and Pharmacology, 2005